Credits Available: 4.75 AMA PRA Category 1 Credits

Description: Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, can prove challenging to address in real-world settings. Although biologics directed against TNF-α can rapidly and sustainably induce clinical remission of these conditions, they have incomplete efficacy; many other conventional treatments used alongside biologics additionally have complex safety profiles that limit their use. These limitations have spurred the development and examination of novel agents, such as Janus Kinase (JAK) inhibitors, in patients with inadequately controlled disease. Through this three-part, small-group educational program, rheumatologists and other supporting healthcare providers can gain greater familiarity with the mechanisms of action behind different JAK inhibitors, evaluate their efficacy and safety in different patient populations, and become acquainted with strategies to improve access to these agents on behalf of their patients. In doing so, clinicians can ensure that the next generation of therapies for immune-mediated inflammatory diseases are used to their fullest potential.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant, Pharmacist
Target Specialties: Rheumatology, Dermatology

Ahmad Qurie

Baptist Hospital
Director of Rheumatology clinic and infusion services

I am a rheumatologist at Baptist Hospital, in Beaumont, TX
I am an internal medicine faculty at the same program.

I am part of ABIM standard setting panel for Rheumatology.
Also, a member of ABIM early career physician group